CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$0.69 USD
-0.01 (-0.88%)
Updated Aug 6, 2025 03:59 PM ET
After-Market: $0.68 -0.01 (-0.79%) 6:14 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Market Cap
As of the previous market close, Can-Fite Biopharma Ltd has a market cap of $5.03M, which represents its share price of $1.42 multiplied by its outstanding shares number of 3.54M. As a small-cap company, CANF's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CANF 0.69 -0.01(-0.88%)
Will CANF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CANF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CANF
CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know
Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now
CANF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CANF
Can-Fite BioPharma (CANF) Reaches Key Enrollment Milestone in Cancer Trial
Can-Fite achieved over 50% enrollment in Phase 2a trial of Namodenoson
Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment ...
Can Fite Biofarma (CANF) Receives "Buy" Rating from Analyst | CANF Stock News
12 Health Care Stocks Moving In Monday's Intraday Session